Ekaterina Galkina Cleary

Contribution of NIH funding to new drug approvals 2010–2016

Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja et al. · Proceedings of the National Academy of Sciences · 2018 · 239 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +11

Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies

Fred D. Ledley, Sarah Shonka McCoy, Gregory Vaughan et al. · JAMA · 2020 · 173 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmaceutical Manufacturing +14

Association of Low-Level Ozone with Cognitive Decline in Older Adults

Ekaterina Galkina Cleary, Manuel Cifuentes, Georges Grinstein et al. · Journal of Alzheimer s Disease · 2017 · 105 citations · Full text

Public Health, Environmental Sciences, Neurology +17

Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019

Ekaterina Galkina Cleary, Matthew J. Jackson, Edward W. Zhou et al. · JAMA Health Forum · 2023 · 57 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

NIH funding for vaccine readiness before the COVID-19 pandemic

Anthony E. Kiszewski, Ekaterina Galkina Cleary, Matthew J. Jackson et al. · Vaccine · 2021 · 37 citations · Full text

Veterinary Medicine, Infectious Diseases, Immunization +14